Pharmaceutical Technology

MAY 25, 2023

The Medicines and Healthcare products Regulatory Agency (MHRA) aims to launch a pilot genetic biobank that will gather patient data to associate drug-related adverse events to their genetic makeup. The Yellow Card biobank will launch as a joint venture with the UK-government funded entity Genomics England on June 1.

Biobanking 130

Biobanking Genetics Genome Project Genome 130

Drug Discovery World

NOVEMBER 23, 2023

Narain , PhD, President and CEO of BPGbio asks how a better calibre of biobanks in life sciences can lead to more drugs making it to market. Not all biobanks are created equal Biobanks provide a treasure trove of clinical data for exploration with AI tools. But the utility of biobanks varies.

Biobanking 57

Biobanking Drugs Medicine Genome 57

Cloudbyz

NOVEMBER 5, 2021

The short answer is that all Biobanks are Biorepositories, but not all Biorepositories are Biobanks. Realistically speaking, the terms “Biobank” and “Biorepository” are used pretty interchangeably. The differences we can point out when someone asks: What is the difference between Biobanks and Biorepositories?

Biobanking 52

Biobanking Research Regulation Scientist 52

BioTech 365

AUGUST 17, 2021

Epigenomics AG / Key word(s): Strategic Company Decision/Change in Forecast Epigenomics AG: Execution of a Biobank Sale Agreement and Update of Guidance 17-Aug-2021 / 21:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) … Continue reading →

Biobanking 40

Biobanking Sales Regulation 40

Drug Discovery World

MARCH 7, 2023

As such, Qatar Biobank has emerged within this modernisation to act as a focal point for the country’s goal in preventive and personalised healthcare. Qatar Biobank could be an essential partner in this.

Biobanking 52

Biobanking Drugs Genome Genomics 52

Cloudbyz

NOVEMBER 3, 2021

Automated Biobanking. Automated Biobanking is an approach to radically reduce the manual tasks involved in properly storing, labeling, authenticating, and monitoring samples, as well as increasing the ease of displaying much of their data values and making sample retrieval easier. Cost Recovery Fees for Biobanks.

Biobanking 52

Biobanking Clinical Research Contamination Research 52

pharmaphorum

NOVEMBER 24, 2022

More than two years on, the EU medicines regulator has now selected the first set of data partners to collaborate with DARWIN EU, which focuses on real-world evidence collected on a patient’s health status or delivery of healthcare from a variety of sources, other than conventional clinical trials.

Big Data 52

Big Data Biobanking Regulation Medicine 52